Global Oncology Based In-Vivo CRO Market Size, Share, Trends, Growth and Forecast 2032

Global Oncology Based In-Vivo CRO Market Insights

According to a report from Zion Market Research, the global Global Oncology Based In-Vivo CRO Market was valued at USD 1.39 Billion in 2023 and is projected to hit USD 3.13 Billion by 2032, with a compound annual growth rate (CAGR) of 8.5% during the forecast period 2024-2032.

This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Global Oncology Based In-Vivo CRO Market industry over the next decade.

The report offers valuation and analysis of the Oncology Based In-vivo CRO market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2018 to 2023 along with a forecast from 2024 to 2032 based on value (USD Billion).

Request Free Sample

Introduction

Oncology models based on Immuno-deficient mice clinical trials are used for carrying out oncology research on human subjects across the globe. Apart from this, introduction of new models such as transgenic mice model of cancer provide the potential of creating more predictive prototypes for cancer. Increase in the cancer cases and huge government investment on oncology research & development activities along with high allocation of funds for CRO researching on cancer drug therapies will prompt the growth of the oncology based in-vivo CRO industry over the forecast timeframe.

Global Oncology Based In Vivo (CRO) Market: Segmentation Analysis

Global Oncology Based In Vivo (CRO) Market, By Indication

• Blood Cancer
• Solid Tumors

Based on Indication, the Global Oncology Based In Vivo (CRO) Market is separated into Blood Cancer and Solid Tumors. Solid tumors dominate the worldwide oncology-based in vivo CRO market due to their higher occurrence and the considerable research needed for targeted medications and individualized treatments. While blood cancers are substantial, they represent a lower fraction of market activity when contrasted to the broader and more diverse research focus on solid tumors.

Global Oncology Based In Vivo (CRO) Market, By Model

• Syngeneic Model
• Xenograft

Based on Model, Global Oncology Based In Vivo (CRO) Market is divided into Syngeneic Model and Xenograft. The xenograft model presently dominates the worldwide oncology-based in vivo CRO market due to its superior capacity to imitate human tumor microenvironments. This paradigm is preferred for assessing therapeutic efficacy and mechanisms in cancer research, as it provides useful information for designing targeted therapies and individualized treatments.

Request Free Sample

Global Oncology Based In Vivo (CRO) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Global Oncology Based In-Vivo CRO Market: Report Scope

Market Growth Dynamics

A surge in the aging population prone to chronic diseases such as cancer is likely to define the expansion of oncology based in-vivo CRO industry over the forecast timeframe. Rise in the innovations in genetic engineering along with growing focus on oncogene study will promulgate the oncology based in-vivo CRO market size.  A prominent increase in the particular treatments for cancer along with easy access to large proportion of medicines along with utilization of oncology based in-vivo CRO for finding new diagnosis & treatment for cancer will prompt the business growth.

Furthermore, massive use of smartphones in healthcare and pharma sectors along with growing internet & social media penetration across the globe is expected to facilitate the emergence of oncology based in-vivo CRO industry over the forecast timeframe. Apparently, the approval of generic medicines by organizations such as U.S. FDA and launch of biosimilars has encouraged the pharma firms to take support of CROs for cancer research & drug development. Such moves will create a strong platform for the growth of the oncology based in-vivo CRO industry over the assessment period.

North America To Contribute Majorly Towards Oncology Based In-Vivo CRO Market Revenue By 2032

The expansion of oncology based in-vivo CRO industry in North America over the assessment timeline is credited to large allocation of funds for cancer research activities in the U.S. Apart from this, presence of mammoth life science & pharma firms in the region and their active involvement in drug development process for cancer treatment will promote the market growth in the sub-continent over the years ahead. Easy availability of strong healthcare facilities in the countries like Canada and the U.S. along with massive requirement of aid from CROs to reputed pharma, healthcare & medical devices, and biotech firms for conducting research pertaining to cancer treatment will provide impetus to the growth of the business in the sub-continent.

Major participants in the industry include -

• Living Tumor Laboratory
• EVOTEC
• Taconic Biosciences
• Charles River Laboratory
• Xentech
• The Jackson Laboratory
• Eurofins Scientific
• MI Bioresearch, Inc.
• Crown Bioscience
• ICON Plc.
• Covance
• Wuxi AppTec
• Champion Oncology, Inc.

The global oncology based in-vivo CRO market is segmented as follows:

By indication:

• Blood cancer
• Syngeneic model
• Solid tumors
• PDX (Patient-Derived Xenograft)
• Xenograft
• Other

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa